First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer

埃罗替尼 医学 肿瘤科 内科学 表皮生长因子受体 肺癌 盐酸厄洛替尼 临床终点 T790米 无进展生存期 癌症 进行性疾病 临床试验 化疗 吉非替尼
作者
Keunchil Park,Chong‐Jen Yu,Sang-We Kim,Meng-Chih Lin,Virote Sriuranpong,Chun-Ming Tsai,Jong-Seok Lee,Jin Hyoung Kang,K.C. Chan,Pablo Ernesto Pérez,Peter Button,Myung‐Ju Ahn,Tony Mok
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:2 (3): 305-305 被引量:208
标识
DOI:10.1001/jamaoncol.2015.4921
摘要

Continuing molecularly targeted treatment beyond disease progression in non-small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses, highlighting the challenge to identify whether progression is the optimal time to switch treatment.To study the efficacy of first-line erlotinib therapy in patients with NSCLC with activating EGFR mutations and postprogression erlotinib therapy.ASPIRATION (Asian Pacific trial of Tarceva as first-line in EGFR mutation) was a phase 2, open-label, single-arm study conducted from 2011 to 2012 in 23 centers in Hong Kong, Korea, Taiwan, and Thailand of adults with stage IV, EGFR mutation-positive NSCLC, with ECOG performance status 0 to 2.Patients received erlotinib 150 mg/d orally until disease progression, after which erlotinib therapy could be continued at patient and/or investigator discretion.The primary end point was progression-free survival (PFS1; time to Response Evaluation Criteria in Solid Tumours 1.1 progression or death). Secondary end points included PFS2 (time to off-erlotinib progression if erlotinib therapy was extended beyond progression at patient and/or investigator discretion), objective response rate, disease control rate, overall survival, and safety. The use of plasma-based assessment of EGFR mutations was also investigated.Of 359 patients screened, 208 were enrolled. Median follow-up was 11.3 (95% CI, 10.9-13.0) months. Of the 207 intent-to-treat patients (62.3% female; median age, 60.8 [range, 28-89] y), 176 had a PFS1 event (171 progression and 5 deaths); of these, 78 discontinued and 93 continued erlotinib therapy following progression. Median PFS1 was 10.8 (95% CI, 9.2-11.1) months. Median PFS1 and PFS2 in the 93 continuing patients was 11.0 (95% CI, 9.2-11.1) and 14.1 (95% CI, 12.2-15.9) months, respectively. Median PFS1 and PFS2 was 11.0 (95% CI, 9.3-12.0) and 14.9 (95% CI, 12.2-17.2) months in patients with exon 19 deletions or L585R mutations. Overall response rate was 66.2%; disease control rate was 82.6%. Median overall survival was 31.0 months (95% CI, 27.3 months to not reached). In the safety population (n = 207) serious adverse events were reported in 27.1%, with events of at least grade 3 experienced by 50.2%. Sensitivity and specificity of plasma-based EGFR mutation analysis was 77% and 92%, respectively.ASPIRATION supports the efficacy of first-line erlotinib therapy in patients with EGFR mutation-positive NSCLC and that treatment beyond progression is feasible and may delay salvage therapy in selected patients.clinicaltrials.gov Identifier: NCT01310036.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
火星上香菇完成签到,获得积分10
2秒前
王雨薇应助忧虑的若灵采纳,获得10
2秒前
赤练仙子完成签到,获得积分10
2秒前
郝憨憨完成签到,获得积分10
2秒前
3秒前
Wzh完成签到,获得积分20
3秒前
3秒前
4秒前
5秒前
开心完成签到 ,获得积分10
5秒前
5秒前
大饼卷肉发布了新的文献求助10
6秒前
6秒前
司徒文青应助geonoob采纳,获得30
7秒前
7秒前
牧紊发布了新的文献求助10
7秒前
Wzh发布了新的文献求助10
8秒前
优秀不愁发布了新的文献求助10
8秒前
第一张发布了新的文献求助10
10秒前
11秒前
任性的白薇完成签到,获得积分10
11秒前
薄荷水发布了新的文献求助10
12秒前
12秒前
不想取名字完成签到,获得积分10
13秒前
13秒前
王雨薇应助忧虑的若灵采纳,获得10
14秒前
ddddddd完成签到 ,获得积分10
14秒前
留胡子的函完成签到,获得积分10
15秒前
levi_heart发布了新的文献求助10
15秒前
Owen应助第一张采纳,获得10
15秒前
黄青青完成签到,获得积分10
17秒前
赫幼蓉完成签到 ,获得积分10
19秒前
20秒前
22秒前
22秒前
加菲丰丰应助xzz采纳,获得30
22秒前
susu完成签到,获得积分10
23秒前
英俊的铭应助Crazy_Runner采纳,获得10
23秒前
23秒前
wwxd完成签到,获得积分10
24秒前
高分求助中
A pan-cancer cuproptosis signature predicting immunotherapy response and prognosis 1500
Straight Talk about ADHD in Girls: How to Help Your Daughter Thrive 1100
Lorenz Luthi - The Regional Cold Wars in Europe, East Asia, and the Middle East Crucial Periods and Turning Points 1000
Models of Teaching(The 10th Edition,第10版!)《教学模式》(第10版!) 800
Full waveform acoustic data processing 500
More Activities for Teaching Positive Psychology A Guide for Instructors 330
The Chicago Manual of Style, 18th Edition 300
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 电极
热门帖子
关注 科研通微信公众号,转发送积分 2888168
求助须知:如何正确求助?哪些是违规求助? 2508958
关于积分的说明 6791675
捐赠科研通 2183956
什么是DOI,文献DOI怎么找? 1161130
版权声明 586654
科研通“疑难数据库(出版商)”最低求助积分说明 569497